Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 12/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282290 | 1.00 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1708659 | 0.85 | ABL1 (0.44) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1282863 | 0.83 | SCD (0.46) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1282865 | 0.83 | SCD (0.46) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1283007 | 0.83 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1709506 | 0.82 | ABL1 (0.42) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1282245 | 0.82 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1292371 | 0.81 | ABL1 (0.41) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1283113 | 0.81 | ABL1 (0.41) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1283010 | 0.78 | ABL1 (0.47) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| EP-2625178-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | Biota Europe Ltd (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| WO-2012045124-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | BIOTA EUROPE LTD (GB) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | NPC1 1032/4885RAB9A 915/4885SMN1; SMN2 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.